It d ti tIntroduction to Illumina Diagnostics · 2016. 11. 3. · Illumina China (Beijing) Illumina...
12
It d ti t Introduction to Illumina Diagnostics Emily Winn-Deen, PhD Vice President, Product Development Diagnostics © 2010 Illumina, Inc. All rights reserved. Illumina, illuminaDx, Solexa, Making Sense Out of Life, Oligator, Sentrix, GoldenGate, GoldenGate Indexing, DASL, BeadArray, Array of Arrays, Infinium, BeadXpress, VeraCode, IntelliHyb, iSelect, CSPro, GenomeStudio, Genetic Energy, and HiSeq are registered trademarks or trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.
Transcript of It d ti tIntroduction to Illumina Diagnostics · 2016. 11. 3. · Illumina China (Beijing) Illumina...
I t d ti tIntroduction to Illumina Diagnostics
Emily Winn-Deen, PhDVice President, Product Development
Diagnostics
© 2010 Illumina, Inc. All rights reserved.Illumina, illuminaDx, Solexa, Making Sense Out of Life, Oligator, Sentrix, GoldenGate, GoldenGate Indexing, DASL, BeadArray, Array of Arrays, Infinium, BeadXpress, VeraCode, IntelliHyb, iSelect, CSPro, GenomeStudio, Genetic Energy, and HiSeq are registered trademarks or trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.
Corporate Overview
Founded in 1998
Initial Public Offering on July 27 2000Initial Public Offering on July 27, 2000
Headquarters in San Diego, CA
More than 500,000 square ft. of facility , q yspace in 6 countries
Over 1,800 employees
IP tf li f 135 i dIP portfolio of 135 issued patents and 168 pending applications
Ranked #1 on Forbes’ list of Fastest Growing T h l C i i 2009 & 2007Technology Companies in 2009 & 2007
Added to the NASDAQ-100 listing in 2008
3
A Global OrganizationExpanded Manufacturing, R&D, Sales, Service & Support
Illumina BV(The Netherlands)
Illumina China(Beijing)
Illumina Cambridge
Illumina KK (Tokyo)Jinan, ChinaChengdu, China
KoreaShanghai
CambridgeIllumina Hayward (Hayward, CA)
Illumina GlobalIndia
Malaysia
VietnamThailandTaiwan
Illumina
Illumina Global Headquarters(San Diego, CA)
Australia
u aSingapore
CommercialMfg/R&D
AustraliaNew Zealand
Over 1800 Employees>150 Sales Personnel
>300 Customer Solutions Personnel
4
Partners
Markets Served
Molecular Dx~$3B
Lif S i
Applied Markets
~$1BLife Sciences~$2.8B
$1B
Consumer
5
Growth Opportunities for Genetic AnalysisTotal Addressable Market
Today: ~$6.6B
Pharma & Applied Markets
High to LowComplexity
Arrays
S iSequencing
6
Market estimates in $billions
Industry Leading GrowthStrong Performance While Reinvesting in New Opportunities
$0.93 $1.00 $700
53% Revenue CAGR
$0 62 $0 70
$0.80
$0.90
$500
$600
RevenueOperating ProfitEPS
$573$662
$0.56
$0.62
$0.50
$0.60
$0.70
$300
$400
$500
$185
$367
$0.20
$0.30
$0.40
$200
$300
$52$94
$169$185
$0.00
$0.10
$0
$100
2006 2007 2008 2009 Estimate
7
Non-GAAP Operating Profit and Earnings per Share
Integrated Solutions That Advance the Understanding of Genetics and Health
BeadXpressHiSeq 2000 iScan BeadXpressHiSeq 2000 iScan
Whole Genome,Regulatory & Whole Genome, Low ComplexityRegulatory &
TargetedSequencing
Targeted & Custom Microarrays
p yTargeted, Custom
Arrays
8
Supporting Rich & Divergent Applications
VARIANT ANALYSIS
METHYLATION ANALYSIS ChIP SEQUENCING
COMPLETE RNA PROFILING
de novo SEQUENCING
9
Resources to Provide Complete Solutions
iControlDB
SystemsAutomation COMPLETESYSTEMSSYSTEMS
Assays &Software
10
Assays &Reagents
Software
Illumina’s Matrixed Organization
Life Sciences Diagnostic
Business Units
FunctionsCommercial Operations
Businessg
Business
Research/Services & New Technologies
Materials &Business Apps
& New Technologies
Market Dev &Collaborations
Legal &Administration
Finance & InvestorRelations
11
IlluminaDx Vision
Our vision is to become a leader in translational medicine, focusing on complex diseases that benefit from high performance analysis, including genotyping, copy number, gene expression, methylation and protein analysis.
We leverage the strength of our technologies in four major areas:
MolecularMolecular Clinical Oncology CytogeneticsDiagnostics Services Discovery
12
The Next Generation of Molecular Diagnostic Tests, Systems, and Services
Seminar Schedule
9 00 R i i9:00 Registration
9:30 Introduction to IlluminaDx Emily Winn-Dean, VP of Product Development of Diagnostics, Illumina
9:45 Maximizing the Multiplexing Capabilities of the BeadXpressSystem
Gianluca Roma, Illumina
10:00 Pharmacogenetics Research Standardized : The ADME CoreList and VeraCode ADME Core Panel
Michael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre
10:30 Identifying Chromosomal Abnormalities Using Infinium SNP BeadChips
Harper VanSteenhouse, PhD, IlluminaandMichael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre
11:15 Clinical Genome Sequencing Service Julianne O’Daniel, CGC, Illumina
12:00 Lunch Café
1:00 A Platform Approach to Translational Cancer Discovery and Di ti D l t
Naomi O’Grady, Illumina
13
Diagnostic Development
1:45 Conclusion
